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Abstrak
Acinetobacter baumannii merupakan spesies Acinetobacter spp. tersering diisolasi dari 
manusia, dan lebih sering dijumpai pada infeksi nosokomial dibandingkan dengan infeksi di 
komunitas. Eksistensi bakteri ini di lingkungan terkait dengan keragaman reservoir, kemampuan 
memperoleh gen pembawa sifat resisten antimikroba, dan sifat resisten terhadap pengeringan. 
Infeksi disebabkan strain A.baumannii yang resisten terhadap banyak antibiotik tidak mudah 
dikendalikan dan menjadi permasalahan di berbagai negara. Penelitian ini bertujuan untuk 
mengetahui prevalensi A.baumannii dari spesimen klinis di instalasi mikrobiologi klinik RSUP 
Haji Adam Malik serta pola kepekaannya terhadap berbagai antibiotik. Identifikasi dan uji 
kepekaan menggunakan mesin otomatis Vitek 2 dengan Advanced Expert System (AES). 
Penelitian ini menemukan 644/3693 (17,44%) isolat A.baumannii dari berbagai spesimen klinis. 
A.baumannii paling banyak diisolasi dari spesimen dahak. Penelitian ini menemukan 147/644 
(23%) bahwa isolat carbapenem-resistent A.baumannii (imipenem dan meropenem). Sebagian 
besar isolat sensitif terhadap colistin, amikacin dan tigecycline. Prevalensi A.baumanni yang 
ditemukan pada penelitian ini adalah rendah namun resistensinya tinggi terhadap antibiotik 
terutama golongan penicillin, cephalosporin dan fluoroquinolon. 
Kata kunci: A. baumannii, spesimen klinis, pola kepekaan, carbapenem-resistent A.baumannii 
Abstract
Acinetobacter baumannii is the most frequent species of Acinetobacter spp. isolated from 
humans and more common in nosocomial infection than it is in community acquired infection. 
A.baumannii existence in environment is associated with the diversity of its reservoirs, its 
capacity to accumulate genes of antimicrobial resistence, and its resistence to desiccation. 
Infection of Multidrug resistent (MDR) strain of A.baumannii is not easy to manage and it has 
become a problem in many countries. The aim of this retrospective study was to investigate 
the prevalence of A.baumannii from routine clinical specimens sent to clinical microbiology 
laboratory RSUP HAM Medan and its susceptibility pattern to various antibiotics. Identification 
and susceptibility testing of A. baumannii was performed by Vitek 2 with Advanced Expert 
System (AES). A total of 644/3693 (17.44%) A.baumannii isolates were identified from various 
clinical specimens. From those isolates, there were 147 (23%) isolates of carbapenem-
resistent A.baumannii (imipenem and meropenem). A.baumannii mainly isolated from sputum 
specimens, and most isolates were highly sensitive to colistin, amikacin and tigecycline. 
Low prevalence of A.baumannii was found in this study. However, the isolates showed high 
resistence level to antibiotics, particularly penicillin, cephalosporin and fluoroquinolones.
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INTRODUCTION 
Acinetobacter are opportunistic Gram-
negative bacilli that occasionally appear 
round on smears (so termed cocobacilli).1 
These bacterias are widely distributed in soil 
and water. They can occasionally be cultured 
from skin, mucous membranes, secretions, 
and hospital environment. A.baumannii 
is the species most commonly isolated. A 
baumannii has been isolated from blood, 
sputum, skin, pleural fluid, and urine, usually 
in device associated infections. Acinetobacter 
encountered in nosocomial pneumonia often 
originates in the water of room humidifiers 
or vaporizers. In patients with A.baumannii 
bacteremia, intravenous catheters are the 
main source of infection. In patients with burns 
or with immune deficiencies, acinetobacter 
acts as an opportunistic pathogen and can 
produce sepsis.2
Acinetobacter strains are often resis-
tent to antimicrobial agents, and therapy 
of infection can be difficult. They respond 
most commonly to gentamicin, amikacin, 
or tobramycin and to newer penicillins or 
cephalosporins.2 To treat serious A. bau-
mannii infections, carbapenems has been 
considered for many years as the drug of 
choice. Until recently, the majority of clinical 
A. baumannii isolates had been sensitive 
to the carbapenems. Unfortunately, the 
rapidly escalating prevalence of carbapenem 
-resistent A.baumannii (CRAB) in many parts 
of the world in the past few years has 
undermined the reliability of carbapenems.3 
A.baumannii resistence to carbapenems 
mediated by the lack    of drug penetration 
(i.e., porin mutations and efflux pumps) and/
or carbapenem-hydrolyzing beta-lactamase 
enzymes such as OXA carbapenamases and 
metallo-beta-lactamases (MBLs).4,5
Recently, a large number of class D OXA-
type  enzymes which against carbapenems 
were characterized in locations that include 
Scotland, Spain, France, Japan, Singapore, 
China, Brazil, Cuba, and Kuwait.6,7 Some 
Acinetobacter strains express class B MBLs, 
which hydrolyze a broad array of antimicrobial 
agents, including carbapenems. MBLs pose 
a significant threat because they are often 
located on mobile genetic elements easily 
transferred among bacteria.7-9  Carbapenem-
resistent isolates of A.baumannii are usually 
resistent to all classes of antimicrobials, and 
show intermediate resistence to rifampin, 
while usually retaining susceptibility to 
tigecycline and colistin.4,10 Susceptibility 
testing should be done to help select the best 
antibiotics for therapy.2
Carbapenem resistence in A. bauman-
nii is now an emerging issue worldwide. 
Surveillance studies indicate that the 
percentage of CRAB isolates gradually 
increased over the last ten years in Europe, 
North and Latin America. Numerous out-
breaks of CRAB were reported from hospitals 
in Northern Europe, Southern Europe and 
the Middle East, North and Latin America, 
Tunisia, South Africa, China, Taiwan, Singa-
pore, Hong Kong, Japan, South Korea and 
Australia.4,10 Outbreaks caused by CRAB 
have also been observed in developing 
countries such as Morocco, Thailand, India 
and Indonesia.10,11 At present, the article of 
CRAB prevalence in Indonesia is limited. 
A study in Sanglah General Hospital Bali 
reported that of all A. baumannii isolates, 
almost 40% was multidrug-resistent and 
three of  them produced carbapenemase.12 
A study in internal medicine ward of dr. 
Soetomo Hospital Surabaya reported that 
9,8% A.baumannii isolated from 467 urine 
specimens and antibiotics were potent to-
wards these isolates.13 In an effort to provide 
information regarding prevalence and anti-
biotic susceptibility pattern of A.baumannii 
isolated from clinical specimens of a hospital 
in Medan, we conducted this study.
METHODS
We conducted a retrospective study 
on various clinical specimens sent to clinical 
microbiology laboratory RSUP HAM, January 
until December 2012. Identification and 
susceptibility testing of A. baumannii were 
performed by Vitek2 system with Advanced 
Expert System (AES). Vitek2 AES is able 
to predict the presence of carbapenemases 
(metallo- or OXA) in A. baumannii. The 
entire beta lactam minimum inhibitory con-
centration (MIC) profile was taken into 
account and analysed by the AES software, 
providing the capability to flag isolates as 
potential carbapenemase producers, even 
those producing a low-level of enzyme.14 
Except for sterile fluids, the clinical 
specimens were cultured in blood agar 
and MacConkey agar, incubated overnight 
at 37°C. The sterile fluids were put in Fan 
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Aerob Culture Bottles (BacT/ALERT), and 
incubated at 37°C for five days. The culture 
bottles with bacterial growth were proceeded 
for Gram stain and primary isolation in 
blood agar and MacConkey agar, incubated 
overnight at 37°C. The pure colonies from 
cultured isolates were picked and mixed 
with three milliliters of sterile saline (0.45% 
NaCl), prepared for inoculum suspension. 
Two tubes were prepared for each isolate. 
The inoculum turbidity was adapted with 
the turbidity of 0.5 McFarland standard 
using Den-sichek. First tube was placed in 
cassette for identification and second tube 
was placed for sensitivity test. A suitable 
Vitek2 card (GN/AST-N089/100) was placed 
according to instruction from bioMérieux. 
The antibiotics used for sensitivity test in 
this study included ampicillin, amoxicillin/ 
clavulanic-acid, ampicillin-sulbactam, mero-
penem, ciprofloxacin, ceftazidime, cefepime 
colistin,  ceftriaxone, cefotaxime, gentamicin, 
imipenem, trimethoprim/sulfametoxazol, to-
bramycin, levofloxacin, tigecycline, amikacin, 
dan piperacillin-tazobactam.
RESULTS AND DISCUSSION 
There are three most clinically relevant 
species of Acinetobacter  that have been 
implicated  in  the  vast  majority of  both 
community-acquired and nosocomial infec-
tions, i.e., A.baumannii, Acinetobacter ge-
nomic species 3 and Acinetobacter ge-
nomic species 13TU. According to the ta-
xonomy, these organisms are classified as 
the A.calcoaceticus-A.baumannii complex, 
together with A.calcoaceticus that have 
frequently been recovered from soil and 
water but has never been implicated in 
serious clinical disease. The three clinically 
relevant members of the A. calcoaceticus-A.
baumannii complex cannot be separated by 
currently available commercial identification 
systems. In fact, A. baumannii, Acinetobacter 
genomic species 3, and Acinetobacter ge-
nomic species 13TU are uniformly identified 
as A.baumannii by the most widely used 
identification systems (including Vitek2). The 
term A.baumannii group for these species 
instead of A. calcoaceticus-A.baumannii 
complex   reflects the fact that A. bauman-
nii, Acinetobacter genomic species 3, and 
Acinetobacter genomic species 13TU sha-
re important clinical and epidemiological 
characteristics and also eliminates the 
confusion resulting from inclusion of an 
environmental species, A.calcoaceticus.4 
Consistent with Vitek2 results, we simply use 
the species name A.baumannii. 
A study revealed that Vitek2 cards were 
promising for rapid identification and reliable 
antibiotic susceptibility test (AST) for most 
species of nonglucosefermenting Gram-ne-
gative bacilli (including Acinetobacter spp.).15 
A study stated that Vitek2 method was the 
only automated susceptibility method that 
satisfied Food and Drug Administration 
(FDA) criteria for approval when used for imi-
penem and meropenem.16 The latter result 
is consistent with the former that observed 
a very major errors (VME) rate of 0.7% for 
the Vitek2 instrument.15,16 Therefore we sup-
posed that our data are reliable enough 
to describe A.baumannii prevalence. We 
successfully identified a total of 644/3693 
(17.44%) isolates of A.baumannii from va-
rious clinical specimens over the period 
January-December 2012 (Figure 1). 
Figure 1.  A.baumannii Prevalence in
 Total  Bacterial Isolates
Vitek2 is able to determine the MIC and 
the production of carbapenemase during one 
test cycle. It detects metabolic changes by 
fluorescence based methods and identifies 
bacteria by monitoring the kinetics of bacterial 
growth. The MIC phenotype detected for the 
test isolate is interpolated with all the patterns 
of the database and the best is identified.17 
We found 147/644 (23%) CRAB (imipenem 
and meropenem). Because the problems of 
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false resistence and false susceptibility with 
imipenem and meropenem may occur, the 
detection of CRAB strains by Vitek2 should 
be confirmed by an additional test14,18 (e.g. 
modified Hodge test, PCR), which we did not 
perform in this study. Therefore, our result 
regarding CRAB prevalence in A.baumannii 
isolat remain as a prediction.
In most institutions, the majority of 
A.baumannii isolates are from the respiretory 
tracts of hospitalized patients.4 A study 
from South Africa revealed that from 232 
CRAB complex isolates, 149 (64.2%) of 
the specimens were from endotracheal as-
pirates.19 Recent  study  from Turkey revealed 
that from 74 strains isolated and identified as 
A. baumannii, most of the strains (46%) were 
isolated from tracheal aspirate specimens, 
and the study results is correspond to three 
other similar studies from Turkey.20 We found 
A.baumannii isolates in sputum 59,94%, 
pus 12,35%, urine 6,02%, blood 4,07%, 
cerebrospinal fluid (CSF) 2,11%, pleural fluid 
0,9%, bronchoalveolar lavage (BAL) 0,3% 
and other specimens 14,31%, as shown in 
Figure 2. Most of A.baumannii were isolated 
from respiratory tract (sputum), therefore our 
result is consistent with previous studies.
Antibiotic susceptibility pattern of 
A.baumannii isolates to some tested antibiotics 
is describe in table 1. Those isolates were 
sensitive to colistin (95.86%), amikacin 
(76.23%), tigecycline (75%), imipenem 
(63.39%), meropenem (62.43%), ampicillin-
sulbactam (57.35%), tobramycin (53.54%) and 
trimethoprim/sulfamethoxazole (51.55%).
Figure 2.  Distribution of A.Baumannii 
Isolates According to Clinical 
Specimens. 
Table 1. Antibiotic Susceptibility Pattern of A.Baumannii isolates
Antibiotic Tested No. tested No. sensitive % sensitive
Amikacin (AN) 551 420 76.23
Amoxicillin-clavulanic acid (AMC) 508 1 0.2
Ampicillin (AM) 644 0 0
Ampicillin-sulbactam (SAM) 136 78 57.35
Cefepime (FEP) 644 242 37.58
Cefotaxime (CTX) 508 85 16.73
Ceftazidime (CAZ) 644 227 35.25
Ceftriaxone (CRO) 136 13 9.56
Ciprofloxacin (CIP) 644 240 37.26
Colistin (CS) 508 487 95.86
Gentamicin (GM) 644 263 40.84
Imipenem (IPM) 508 322 63.39
Levofloxacin (LEV) 644 250 38.82
Meropenem (MEM) 551 344 62.43
Piperacillin/tazobactam (TZP) 642 248 38.63
Tigecycline (TGC) 644 483 75
Tobramycin (TM) 508 272 53.54
Trimethoprim/sulfamethoxazole (SXT) 644 332 51.55
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In this study, the sensitivity test 
results of A.baumannii towards ampicillin-
sulbactam, imipenem, tobramycin mero-
penem, trimethoprim/ sulfamethoxazole 
were tolerable. Ampicillin-sulbactam or a 
carbapenem (imipenem or meropenem) 
is adequate for the treatment of infections 
caused by antibiotic-susceptible strains of 
Acinetobacter spp.21 A study of A. baumannii 
bacteremia in patients who presented with 
critical illness found that patiens with empirical 
combination therapy (e.g., carbapenem 
plus sulbactam or an aminogycoside) had 
a lower mortality rate than patients with 
monotherapy.22 We found high (76.23%) 
amikacin-sensitive  A. baumannii isolates, 
so this recommendation may be important 
for critical patients at risk of A. baumannii 
infections or in the clinical settings of the 
presence of MDR A. baumannii.22 
Among the antibiotics that are considered 
as agents against MDR A. baumannii, 
tigecycline has received significant attention. 
Where the dissemination of MBLs accounts 
for the increasing prevalence of CRAB, the 
combination of colistin and rifampin with or 
without tigecycline should be considered. 
But there have been reports of A. baumannii 
resistence to tigecycline.21 In this study, we 
found 25% tigecycline-resistent A. baumannii 
isolates. We found those isolates were 
most sensitive to colistin (95.87%), and our 
result is correspond to the previous studies 
from India23 and Morocco.24 When CRAB is 
suspected, intravenous colistin combined with 
rifampin and imipenem is a recommended 
therapy.21 However, the optimal empirical 
combination regimens directed against A. 
baumannii infections should be based on 
local antimicrobial susceptibility patterns.22
A. baumannii rate of carriage by 
hospitalized patients is high. It causes a 
variety of nosocomial infections, comprising 
of bacteremia, urinary tract infection, surgical 
site infection and ventilator-associated 
pneumonia, mainly in intensive care unit 
(ICU) patients. It has emerged as a major 
cause of hospital acquired infections and 
unfortunately, some of them are MDR strains 
which probably caused by extensive use 
of antimicrobial agents. A. baumannii has 
a broad range of resistence mechanisms 
to all existing antibiotic classes and a 
capacity to acquire new determinants of 
resistence.4,10,19,25 Genome sequence analysis 
of six A. baumannii clinical strains has shown 
the presence of a resistence island with a 
variable composition of resistence genes 
interspersed with transposons, integrons, 
and other mobile genetic elements in three 
of them. Plasmids carrying resistence genes 
involved in horizontal gene transfer have 
been described in A. baumannii strains.10,26,27 
A study showed that infections with MDR 
Acinetobacter are associated with length of 
hospitalization and its mortality rate higher 
than patients with infection by susceptible 
Acinetobacter.28
Within the last five years, the increasing 
number of CRAB is of major importance in 
the context of resistence to beta lactams.24 
Between 1998 and 2004, this rate of 
resistence in Europe, North America, South 
America, and Asia ranged between 0% and 
40%.21 But in most studies after 2005, the 
rate of resistence was greater than 50%. 
High rates of resistence were found in India 
(90%), Morocco (74%), Iran (63%), Italy 
(62,5%), China (55,6%), Turkey (53,7%), 
Korea (51%),23,24,29-33 A study in ICU Cipto 
Mangunkusumo Hospital Jakarta found 
high rate of resistence (50.5%).34  Sanglah 
Hospital Bali showed a moderate rate of 
resistence (36,9%).12 To compare CRAB 
prevalence with previous studies, we still 
need confirmation of Vitek2 CRAB results by 
additional test (e.g.,modified Hodge test). 
CONCLUSION
We  found  low  prevalence of A.bauman-
nii, and most of them are from sputum. 
Those isolates showed high resistence 
level to antibiotics, particularly penicillin, 
cephalosporin and fluoroquinolones. 
We detected CRAB prevalence from the 
isolates, but we need to perform additional 
tests in further studies to confirm the result. 
Antibiotic susceptibility pattern presented 
in this study may help clinicians to select 
appropriate empirical antimicrobial therapy 
for A. baumannii infections.
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